# Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer

> **NCT02808143** · PHASE1 · COMPLETED · sponsor: **Northwestern University** · enrollment: 9 (actual)

## Conditions studied

- Recurrent Bladder Carcinoma
- Stage 0a Bladder Urothelial Carcinoma
- Stage 0is Bladder Urothelial Carcinoma
- Stage I Bladder Cancer

## Interventions

- **BIOLOGICAL:** BCG Solution
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02808143
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-10
- **Primary completion:** 2020-05-15
- **Final completion:** 2022-08-05
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2024-06-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02808143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02808143, "Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02808143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*